Clinical trials in ALS: what did we learn from recent trials in humans?

@article{Meininger2005ClinicalTI,
  title={Clinical trials in ALS: what did we learn from recent trials in humans?},
  author={Vincent Meininger},
  journal={Neuro-degenerative diseases},
  year={2005},
  volume={2 3-4},
  pages={208-14}
}
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. No treatment is currently able to stop the disease process. In the absence of new active compounds there is an urgent need to develop new strategies based on the neuroprotective activity of available drugs. ALS is a heterogeneous disease. To build up these therapeutic trials, we need to have a better understanding of the prognostic factors in this disease. During the Phase IV Rilutek Trial in France, we developed in… CONTINUE READING